エンヴァリス, which develops next-generation equity research, has entered into a research coverage agreement with GMO GlobalSign Holdings. Under the agreement, it plans to begin distributing reports from the third quarter of the fiscal year ending December 2026.
エンヴァリス, which develops a next-generation equity research platform, announced that it had entered into a research coverage agreement with GMO GlobalSign Holdings. The agreement will establish a framework under which the two companies provide an assessment of GMO GlobalSign Holdings' corporate value as a company covered by エンヴァリス's report service.
Under the agreement, エンヴァリス will distribute multifaceted analytical reports, including flash reports issued immediately after earnings announcements, in 3 languages: Japanese, English and Chinese. The distribution network is expected to be broadly developed for investors in Japan and overseas, covering terminals for global financial institutions, domestic investment information services and social media.
Reports are expected to begin distribution from the third quarter of the fiscal year ending December 2026, with analyst reports to be posted after coverage begins. エンヴァリス also provides information on GMO GlobalSign Holdings' corporate information and reports pages.
The counterparty to the agreement is GMO GlobalSign Holdings, whose core businesses are electronic authentication and electronic contracts. ENVALITH is being developed as a platform that provides valuations from an independent perspective for overseas institutional investors as well.